Drug Repositioning in Oncology.
Journal
American journal of therapeutics
ISSN: 1536-3686
Titre abrégé: Am J Ther
Pays: United States
ID NLM: 9441347
Informations de publication
Date de publication:
Historique:
pubmed:
30
4
2019
medline:
30
9
2021
entrez:
30
4
2019
Statut:
ppublish
Résumé
The worldwide increase in the occurrence of cancer associated with the limitations of immunotherapy and the emergence of resistance have impaired the prognosis of cancer patients, which leads to the search for alternative treatment methods. Drug repositioning, a well-established process approved by regulatory agencies, is considered an alternative strategy for the fast identification of drugs, because it is relatively less costly and represents lower risks for patients. We report the most relevant studies about drug repositioning in oncology, emphasizing that its implementation faces financial and regulatory obstacles, making the creation of incentives necessary to stimulate the involvement of the pharmaceutical industry. We present 63 studies in which 52 non-anticancer drugs with anticancer activity against a number of malignancies are described. Some have already been the target of phase III studies, such as the Add-Aspirin trial for nonmetastatic solid tumors, as well as 9 other drugs (aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, and sertraline) in the CUSP9* clinical trial for the treatment of recurrent glioblastoma. Others have already been successful in repositioning such as thalidomide, zoledronic acid, celecoxib, methotrexate, and gemcitabine. Therefore, drug repositioning represents a promising alternative for the treatment of oncological disorders; however, the support from funding agencies and from the government is still needed, the latter regarding regulatory issues.
Sections du résumé
BACKGROUND
BACKGROUND
The worldwide increase in the occurrence of cancer associated with the limitations of immunotherapy and the emergence of resistance have impaired the prognosis of cancer patients, which leads to the search for alternative treatment methods. Drug repositioning, a well-established process approved by regulatory agencies, is considered an alternative strategy for the fast identification of drugs, because it is relatively less costly and represents lower risks for patients.
AREAS OF UNCERTAINTY
UNASSIGNED
We report the most relevant studies about drug repositioning in oncology, emphasizing that its implementation faces financial and regulatory obstacles, making the creation of incentives necessary to stimulate the involvement of the pharmaceutical industry.
DATA SOURCES
METHODS
We present 63 studies in which 52 non-anticancer drugs with anticancer activity against a number of malignancies are described.
THERAPEUTIC INNOVATIONS
UNASSIGNED
Some have already been the target of phase III studies, such as the Add-Aspirin trial for nonmetastatic solid tumors, as well as 9 other drugs (aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, and sertraline) in the CUSP9* clinical trial for the treatment of recurrent glioblastoma. Others have already been successful in repositioning such as thalidomide, zoledronic acid, celecoxib, methotrexate, and gemcitabine.
CONCLUSIONS
CONCLUSIONS
Therefore, drug repositioning represents a promising alternative for the treatment of oncological disorders; however, the support from funding agencies and from the government is still needed, the latter regarding regulatory issues.
Identifiants
pubmed: 31033488
pii: 00045391-202102000-00009
doi: 10.1097/MJT.0000000000000906
doi:
Substances chimiques
Itraconazole
304NUG5GF4
Ritonavir
O3J8G9O825
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e111-e117Informations de copyright
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr. Accessed July 20, 2018.
The Lancet Oncology. Calling time on the immunotherapy gold rush. Lancet Oncol. 2017;18:981.
Markman M. Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer. Gynecol Oncol. 2013;131:241–245.
Wiggins HL, Wymant JM, Solfa F, et al. Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells. Biochem Pharmacol. 2015;93:332–342.
Kim M, Choe MH, Yoon YA, et al. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells. Biochem Pharmacol. 2017;144:78–89.
Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3:673–683.
Dilly SJ, Clark AJ, Marsh A, et al. A chemical genomics approach to drug reprofiling in oncology: antipsychotic drug risperidone as a potential adenocarcinoma treatment. Cancer Lett. 2017;393:16–21.
Mehndiratta MM, Wadhai SA, Tyagi BK, et al. Drug repositioning. Int J Epilepsy. 2016;3:91–94.
Li J, Huang Y, Gaob Y, et al. Antibiotic drug rifabutin is effective against lung cancer cells by targeting the eIF4E-β-catenin axis. Biochem Biophysical Res Commun. 2016;472:299–305.
Serafin MB, Hörner R. Drug repositioning, a new alternative in infectious diseases. Braz J Infect Dis. 2018;22:252–256.
Brown AS, Patel CJ. A standard database for drug repositioning. Sci Data. 2017;4:170029.
Verbaanderd C, Meheus L, Huys I, et al. Repurposing drugs in oncology: next steps. Trends Cancer. 2017;3:543–546.
Kast RE, Karpel-Massler G, Halatsch ME. CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget. 2014;5:8052–8082.
Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31–41.
Din FV, Theodoratou E, Farrington SM, et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut. 2010;59:1670–1679.
Coyle C, Cafferty FH, Rowley S, et al. ADD-ASPIRIN: a phase III, doubleblind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemp Clin Trials. 2016;51:56–64.
Gupta SC, Sung B, Prasad S, et al. Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci. 2013;34:508–517.
Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–1952.
Zhang Y, Cao Y, Sun X, et al. Chloroquine (CQ) exerts anti-breast cancer through modulating microenvironment and inducing apoptosis. Int Immuno Pharmacol. 2017;42:100–107.
Zhelev Z, Ohba H, Bakalova R, et al. Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Phenothiazines and leukemia. Canc Chemother Pharmacol. 2004;53:267–275.
Serafeim A, Holder MJ, Grafton G, et al. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood. 2003;101:3212–3219.
Wang Z, Tan J, McConville C, et al. Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells. Nanomedicine. 2017;13:641–657.
Duan L, Shen H, Zhao G, et al. Inhibitory effect of Disulfiram/copper complex on non-small cell lung cancer cells. Biochem Biophysical Res Commun. 2014;446:1010–1016.
Hoda M, Pajaniradje S, Shakya G, et al. Anti-proliferative and apoptosis-triggering potential of disulfiram and disulfiram-loaded polysorbate 80-stabilized PLGA nanoparticles on hepatocellular carcinoma Hep3B cell line Nanomedicine. Nanotechnology, Biol Med. 2016;12:1641–1650.
Ketola K, Kallioniemi O, Iljin K. Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells. PLoS One. 2012;7:51470.
Liu P, Brown S, Goktug T, et al. Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br J Cancer. 2012;107:1488–1497.
Liu P, Brown S, Channathodiyil P, et al. Disulfiram, an antialcoholism drug, targets breast cancer and glioblastoma stem-like cells. Eur J Cancer. 2012;48:S25–S288.
Xu B, Shi P, Fombon IS, et al. Disulfiram/copper complex activated JNK/c-jun pathway and sensitized cytotoxicity of doxorubicin in doxorubicin resistant leukemia HL60 cells. Blood Cell Mol Dis. 2011;47:264–269.
Yip NC, Fombon IS, Liu P, et al. Disulfiram modulated ROS–MAPK and NFkB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer. 2011;104:1564–1574.
Sharmaa S, Baksib R, Agarwal M. Repositioning of anti-viral drugs as therapy for cervical cancer. Pharmacol Rep. 2016;68:983–989.
Engelhardt M, Terpos E, Kleber M, et al. European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014;99:232–242.
Song M, Wu H, Wu S, et al. Antibiotic drug levofloxacin inhibits proliferation and induces apoptosis of lung cancer cells through inducing mitochondrial dysfunction and oxidative damage. Biomed Pharmacother. 2016;84:1137–1143.
Yu M, Li R, Zhang J. Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast cancer. Biochem Biophys Res Commun. 2016;471:639–645.
Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res. 2010;3:1451–1461.
Bodmer M, Meier C, Krähenbühl S, et al. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010;33:1304–1308.
Kumar S, Meuter A, Thapa P, et al. Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer. 2013;119:555–562.
Zhang ZJ, Li S. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:707–710.
Tan BK, Adya R, Chen J, Lehnert H, Sant Cassia LJ, Randeva HS. Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol. Metab. 2011;96:808–816.
Vortherms AR, Dang HN, Doyle RP. Anticancer conjugates and cocktails based on methotrexate and nucleoside synergism. Clin Med Oncol. 2009;3:19–26.
Chow WA, Jiang C, Guan M. Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol. 2009, 10:61–71.
Russo A, Pellosib DS, Pagliaraa V, et al. Biotin-targeted Pluronic1 P123/F127 mixed micelles delivering niclosamide: a repositioning strategy to treat drug-resistant lung cancer cells. Int J Pharmaceutics. 2016;511:127–139.
Wang YC, Chao TK, Chang CC, et al. Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells. PLoS One. 2013;8:e74538.
Sung B, Ahn KS, Aggarwal BB. Noscapine, a benzylisoquinoline alkaloid, sensitizes leukemic cells to chemotherapeutic agents and cytokines by modulating the NF-kappaB signaling pathway. Cancer Res 2010;70:3259–3268.
Wiklund ED, Catts VS, Catts SV, et al. Cytotoxic effects of antipsychotic drugs implicate cholesterol homeostasis as a novel chemotherapeutic target. Int J Cancer. 2010;126:28–40.
Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372:735–746.
Pasquier E, Joseph C, Carre M, et al. Propranolol potentiates the anti-angiogenic effects and antitumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011;2:797–809.
Pasquier E, Street J, Pouchy C, et al. β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. Br J Cancer. 2013;108:2485–2494.
Kalogera E, Roy D, Khurana A, et al. Quinacrine in endometrial cancer: repurposing an old antimalarial drug. Gynecol Oncol. 2017;146:187–195.
Eriksson A, Osterroos S, Hassan J, et al. Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia. Blood Cancer J. 2015;5:e307.
Preet R, Mohapatra P, Mohanty S, et al. Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity. Int J Cancer. 2012;130:1660–1670.
Preet R, Siddharth S, Satapathy SR, et al. Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade. Biochem Pharmacol. 2016;105:23–33.
Sotelo J, Guevara P, Reyes S, et al. Interstitial quinacrine for elimination of abnormal tissue; therapy of experimental glioma. Surgery. 2000;128:439–446.
Mohapatra P, Preet R, Das D, et al. Quinacrine-mediated autophagy and apoptosis in colon cancer cells is through a p53- and p21-dependent mechanism. Oncol Res. 2012;20:81–91.
Wu X, Wang Y, Wang H, et al. Quinacrine inhibits cell growth and induces apoptosis in human gastric cancer cell line SGC-7901. Curr Ther Res Clin Exp. 2012;73:52–64.
Récher C, Beyne-Rauzy O, Demur C, et al. Antileukemicactivity of rapamycin in acute myeloid leukemia. Blood. 2005;105:2527–2534.
Sillaber C, Mayerhofer M, Böhm A, et al. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest. 2008;38:43–52.
Gil-Ad I, Zolokov A, Lomnitski L, et al. Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancerxenografted mice. Int J Oncol. 2008;33:277-286.
Ahn KS, Sethi G, Aggarwal BB. Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kB pathway. Biochem Pharmacol. 2008;75:907–913.
Paravar T, Lee DJ. Thalidomide: mechanisms of action. Int Rev Immunol. 2008;27:111–135.
Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–1571.
Rose JS, Bekaii-Saab TS. New developments in the treatment of metastatic gastric cancer: focus on trastuzumab. Onco Targets Ther. 2011;4:21–26.
Yeh CT, Wu AT, Chang PM, et al. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am J Respir Crit Care Med. 2012;186:1180–1188.
Budd GT, Bukowski RM, Lichtin A, et al. Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer. Invest N Drugs. 1993;11:75e79.
Murren JR, Durivage HJ, Buzaid AC, et al. Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer. Canc Chemother Pharmacol. 1996;38:65–70.
Naftalovich S, Yefenof E, Eilam Y. Antitumor effects of ketoconazole and trifluoperazine in murine T-cell lymphomas. Canc Chemother Pharmacol. 1991;28:384–390.
Kang S, Hong J, Lee JM, et al. Trifluoperazine, a well-known antipsychotic, inhibits glioblastoma invasion by binding to calmodulin and disinhibiting calcium release channel IP3R. Mol Canc Ther. 2017;16:217–227.
Osuka S, Takano S, Watanabe S, et al. Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain. Neurol Med Chir. 2012;52:186–193.
Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125–1132.
Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360:679–691.
Facchini G, Caraglia M, Morabito A, et al. Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. Cancer Biol Ther. 2010;10:543–548.
Meyers PA, Healey JH, Chou AJ, et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer. 2011;117:1736–1744.
Mackiewicz-Wysocka M, Pankowska M, Wysocki PJ. Progress in the treatment of bone metastases in cancer patients. Expert Opin Investig Drugs. 2012;21:785–795.
Meyer LM, Miller FR, Rowen MJ, et al. Treatment of acute leukemia with amethopterin (4-amino, 10-methyl pteroyl glutamic acid). Acta Haematol. 1950;4:157–167.
Pazdur R. FDA Approval for Gemcitabine Hydrochloride: National Cancer Institute at the National Institutes of Health; 2011. Available at: http://www.cancer.gov/cancertopics/druginfo/fda-gemcitabine-hydrochloride. Accessed September 3, 2018.